LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Eli Lilly's pill, orforglipron, is a step closer to becoming the first needle-free alternative in the booming market for weight loss drugs.

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with obesity or overweight with weight-related comorbidities.

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations. Management raised 2025 guidance to ranges of $60 billion-$62 billion in revenue ...

Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, ...